Price History

Hover for the daily close. The dotted line marks the period open.

Compare ORIC with… →

ORIC Key Statistics

As of Sep 4, 2026

Trading

Open: $12.51
Previous Close: $12.74
Day's Range: 12.51–12.99
52-Week Range: 7.23–14.93
Volume: 991.40K
Beta: 0.99

Valuation

Market Cap: $1.33B
P/E Ratio: unprofitable
EPS (ttm): −1.31

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$129.47M
Profit margin: 0.00%
Shares Outstanding: 103.65M
1-Year Return: +19.41%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 1.57M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ORIC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+31.35%−56.57%−59.93%+56.20%−12.28%+1.36%+57.21%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	+57.21%
2025	+1.36%
2024	−12.28%
2023	+56.20%
2022	−59.93%
2021	−56.57%
2020 (partial year)	+31.35%

As of September 4, 2026.

ORIC Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$129.47M	—
2024	$0.00	−$127.85M	—
2023	$0.00	−$100.70M	—
2022	$0.00	−$89.12M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$143.00M	−$129.47M	—
2024	$0.00	—	−$142.90M	−$127.85M	—
2023	$0.00	—	−$110.78M	−$100.70M	—
2022	$0.00	—	−$86.77M	−$89.12M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ORIC Valuation vs Biotechnology Median

Median of 656 stocks

Metric	ORIC	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ORIC Pharmaceuticals, Inc. (ORIC) is capitalised at $1.33B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 111 employees.

The most recent close on file for ORIC is $12.86, dated September 4, 2026. That is +$0.12 (+0.94%) against the previous close. The 52-week range on file runs from $7.23 to $14.93. The latest close sits 77.87% above that 52-week low.

Financial Health

In fiscal 2025, ORIC Pharmaceuticals, Inc. reported revenue of $0.00. The same year closed with a net loss of $129.47M. The reported profit margin is 0%. Trailing earnings per share are −1.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +19.41%. Measured over 5 years, that is −10.98% a year compounded. The reported beta is 0.99. Daily returns over the trailing 6 years annualize to a volatility of 88.16%.

Growth & Income

No dividend is on file for ORIC.

2026 is still running; the price is +57.21% year to date. Across the complete calendar years on file, 2023 returned +56.20% and 2022 returned −59.93%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

ORIC Pharmaceuticals, Inc. (ORIC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
ORIC Pharmaceuticals, Inc.	ORIC	$1.33B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. ORIC Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Visit website →

ORIC Pharmaceuticals, Inc. (ORIC) Stock Analysis